GALAD模型在诊断HBV相关肝细胞癌中的价值探讨

肝脏 ›› 2020, Vol. 25 ›› Issue (3): 291-294.

GALAD模型在诊断HBV相关肝细胞癌中的价值探讨

冯文杏, 周小舟, 韩志毅, 孙新锋, 马文峰, 张卫

518000 广东广州中医药大学第四临床医学院

收稿日期:2019-05-09 出版日期:2020-03-31 发布日期:2020-04-16
通讯作者: 周小舟,Email:zxz0818@hotmail.com
基金资助:
深圳市科技计划项目(JCYJ20170817094901026;JCYJ20180302173542393)

Received:2019-05-09 Online:2020-03-31 Published:2020-04-16

摘要/Abstract

摘要： 目的探讨GALAD模型在HBV相关肝细胞癌中的诊断价值。方法回顾性分析204例HBV感染住院患者,根据诊断分为HCC组及对照组,比较AFP、AFP-L3%、异常凝血酶原(DCP)、三项联合及GALAD模型诊断HCC的受试者工作曲线(ROC)下面积(AUC)、敏感性、特异性差异。结果 HCC组中AFP、AFP-L3%、DCP及GALAD模型Z值水平均高于对照组,AFP、AFP-L3%、DCP单项、三者联合及GALAD模型诊断的AUC分别为0.760、0.742、0.865、0.887,0.937,GALAD模型AUC与三项标志物及其联合的AUC两两比较,差异均有统计学意义(P<0.05)。GALAD模型诊断的敏感性为83.82%,高于AFP、AFP-L3、DCP单项,与三项并联相当,特异性为86.03%。结论 GALAD模型在HBV相关HCC诊断中显示了良好的效能,优于AFP、AFP-L3%、DCP及三项联合诊断,具有一定临床参考价值。

关键词: 肝细胞癌, 甲胎蛋白, 甲胎蛋白异质体L3, 异常凝血酶原, GALAD模型

冯文杏, 周小舟, 韩志毅, 孙新锋, 马文峰, 张卫. GALAD模型在诊断HBV相关肝细胞癌中的价值探讨[J]. 肝脏, 2020, 25(3): 291-294.

参考文献 16

[1]	Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol, 2017,67:302-309.
[2]	Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol, 2017,3:1683-1691.
[3]	Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization, 2015.
[4]	Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011,53:1020-1022.
[5]	Johnson P J, Pirrie S J, Cox T F, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiology Biomarkers & Prevention, 2014,23:144-153.
[6]	Barletta E, Tinessa V, Daniele B. Screening of hepatocellular carcinoma: role of the alpha-fetoprotein (AFP) and ultrasonography . Recenti Prog Med, 2005,96:295-299, 328.
[7]	Marrero J A. Screening tests for hepatocellular carcinoma. Clin Liver Dis, 2005,9:235-251.
[8]	中华人民共和国国家卫生和计划生育委员会,原发性肝癌诊疗规范2017年版.临床肝胆病杂志,2017,33:1419-1431.
[9]	Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta, 2013,425:212-220.
[10]	Jia Z, Wang L, Liu C, et al. Evaluation of alpha-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn), 2014,18:192-196.
[11]	Durazo F A, Blatt L M, Corey W G, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 2008,23:1541-1548.
[12]	Volk M L, Hernandez J C, Su G L, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark, 2007,3:79-87.
[13]	Lim T S, Kim D Y, Han K H, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol, 2016,51:344-353.
[14]	Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol, 2016,14:875-886.
[15]	林清标,董菁,柯坤宇等,GALAD模型在肝细胞癌患者中的诊断价值验证.中华肝脏病杂志,2018,26:621-623.
[16]	Yang J D, Addissie B D, Mara K C, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev, 2019,28:531-538.